Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading ... (atment-relatedAEs were experienced by a ...)

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

Date:6/17/2008

atment-related AEs were experienced by a total of 10.2 percent of patients [11.1 percent of patients (n=225) in the once-daily group and 9.4 percent of patients (n=234) in the twice-daily group]. A total of 3.9 percent of patients experienced serious AEs [4 percent of patients (n=225) in the once-daily group and 3.8 percent of patients (n=234) in the twice-daily group], most of which were gastrointestinal disorders, and only one serious AE was considered to be related to study treatment.

The secondary endpoints of the study evaluated maintenance of remission and relapse rates over 12 months. In the efficacy population at entry (month 0), 78.1 percent of patients (n=219) in the once-daily group and 82.3 percent of patients (n=232) in the twice-daily group were in clinical and endoscopic remission. At month 12, 64.4 percent of patients in the once-daily and 68.5 percent of patients in the twice-daily group were in strictly defined clinical and endoscopic remission (P=0.351). Thus, there was no significant difference between the once-daily and twice-daily groups with respect to strictly defined clinical and endoscopic remission at month 12. Further, 88.9 percent and 93.2 percent of patients in each group, respectively, had maintained clinical remission and were considered "relapse-free".

Study Background

A total of 459 patients were enrolled and randomized in the 303 long-term safety study (246 directly from the parent studies 301 and 302 -- Lialda's eight-week, Phase III, placebo-controlled trials that demonstrated efficacy for the induction of remission in active, mild to moderate UC -- and 213 patients who received an additional 8 weeks of treatment with Lialda 4.8 g/day to induce remission). Remission was defined using stringent clinical and endoscopic measures: modified UC Disease Activity Index (UC-DAI) score of less than or equal to 1, with scores of 0 for rectal bleeding and stool frequency, and a combined Physician's Global Assessment and
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Some patients may not need insulin for long-term control of type 2 diabetes
2. New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
3. Social Security Statement Advises Seniors to Consider Private Long-Term Care Insurance, LTC Agency Reports; Medicare Wont Cover It
4. Treatment at an AASM accredited sleep center improves long-term CPAP compliance
5. Poor sleep a problem in long-term breast cancer survivors
6. Long-term pesticide exposure may increase risk of diabetes
7. Long-term bouts with hay fever worsen ability to breathe through your nose
8. Keane Wins $1.5 Million Electronic Medical Record (EMR) Implementation with Leading Long-Term Care Company
9. Long-term hormone replacement therapy increases breast cancer risk
10. Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
11. Long-term cognitive decline in bypass patients not due to surgery

Post Your Comments:

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading ...(atment-relatedAEs were experienced by a ...),Health